Barnett B, Arakelian M, Beebe D, Ontko J, Riegal C, Siu W
Psychedelic Med (New Rochelle). 2025; 2(1):1-9.
PMID: 40051760
PMC: 11658671.
DOI: 10.1089/psymed.2023.0036.
Downey A, Bradley E, Lerche A, ODonovan A, Krystal A, Woolley J
Psychedelic Med (New Rochelle). 2025; 2(2):61-73.
PMID: 40051581
PMC: 11658676.
DOI: 10.1089/psymed.2023.0051.
Tiedge C, Valido A, Rivas-Koehl M, Garcia B, Robinson L, Clements G
Prev Sci. 2025; .
PMID: 39934543
DOI: 10.1007/s11121-025-01783-1.
Izmi N, Carhart-Harris R, Kettner H
Front Child Adolesc Psychiatry. 2025; 3():1364617.
PMID: 39816600
PMC: 11732004.
DOI: 10.3389/frcha.2024.1364617.
Collins H
Int J Neuropsychopharmacol. 2024; 27(12).
PMID: 39611453
PMC: 11635828.
DOI: 10.1093/ijnp/pyae057.
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Sabe M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L
Mol Psychiatry. 2024; 30(3):1223-1255.
PMID: 39592825
PMC: 11835720.
DOI: 10.1038/s41380-024-02800-5.
Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports.
Yildirim B, Sahin S, Gee A, Jauhar S, Rucker J, Salgado-Pineda P
Psychol Med. 2024; :1-13.
PMID: 39564729
PMC: 11650183.
DOI: 10.1017/S0033291724002496.
Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey.
Stroud J, Rice C, Orsini A, Schlosser M, Lee J, Mandy W
Psychopharmacology (Berl). 2024; 242(2):373-387.
PMID: 39367164
DOI: 10.1007/s00213-024-06685-8.
Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report.
Federico S, Geo M, Entela M, Bachmann S, Elisa R, Silvio C
Clin Case Rep. 2024; 12(9):e9305.
PMID: 39219779
PMC: 11364487.
DOI: 10.1002/ccr3.9305.
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F
CNS Drugs. 2024; 38(10):771-789.
PMID: 39033264
DOI: 10.1007/s40263-024-01101-3.
Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.
Shah F, Shehzadi S, Akram F, Ul Haq I, Javed B, Sabir S
Mol Biotechnol. 2023; 67(1):36-53.
PMID: 38117395
DOI: 10.1007/s12033-023-00994-7.
A first study on the usability and feasibility of four subtypes of suicidality in emergency mental health care.
de Winter R, Meijer C, van den Bos A, Kool-Goudzwaard N, Enterman J, Gemen M
BMC Psychiatry. 2023; 23(1):878.
PMID: 38012641
PMC: 10680224.
DOI: 10.1186/s12888-023-05374-8.
Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the "high-risk" addiction patient.
Black T
Front Psychiatry. 2023; 14:1159843.
PMID: 37799400
PMC: 10548230.
DOI: 10.3389/fpsyt.2023.1159843.
Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.
Bouso J, Revesz D, Ona G, Rossi G, Rocha J, Dos Santos R
Sci Rep. 2023; 13(1):14052.
PMID: 37696900
PMC: 10495368.
DOI: 10.1038/s41598-023-41199-x.
Unraveling the In Vitro Toxicity Profile of Psychedelic 2C Phenethylamines and Their -Benzylphenethylamine (NBOMe) Analogues.
Martins D, Gil-Martins E, Cagide F, da Fonseca C, Benfeito S, Fernandes C
Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37631071
PMC: 10458253.
DOI: 10.3390/ph16081158.
Medical student attitudes and perceptions of psychedelic-assisted therapies.
Li I, Fong R, Hagen M, Tabaac B
Front Psychiatry. 2023; 14:1190507.
PMID: 37441143
PMC: 10335742.
DOI: 10.3389/fpsyt.2023.1190507.
Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".
Al-Imam A, Motyka M, Hoffmann B, Magowska A, Michalak M
Pharmaceuticals (Basel). 2023; 16(6).
PMID: 37375778
PMC: 10302259.
DOI: 10.3390/ph16060831.
The development of psilocybin therapy for treatment-resistant depression: an update.
Borissova A, Rucker J
BJPsych Bull. 2023; 48(1):38-44.
PMID: 37357767
PMC: 10801413.
DOI: 10.1192/bjb.2023.25.
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics.
Urban M, Stingl M, Meinhardt M
Front Neurosci. 2023; 17:1156319.
PMID: 37139521
PMC: 10149865.
DOI: 10.3389/fnins.2023.1156319.
Hallucinations and Hallucinogens: Psychopathology or Wisdom?.
Bouso J, Ona G, Kohek M, Dos Santos R, Hallak J, Alcazar-Corcoles M
Cult Med Psychiatry. 2023; 47(2):576-604.
PMID: 36633720
PMC: 9838303.
DOI: 10.1007/s11013-022-09814-0.